Bavarian Nordic bags vaccine order after confirmed monkeypox cases
Danish vaccine developer Bavarian Nordic (OMX: BAVA) revealed today that it has secured a contract with an undisclosed European country to supply its Imvanex smallpox vaccine in response to new cases of monkeypox evolving during May 2022.
Although no financial terms of the contract were not disclosed, Bavarian Nordic’s shares leapt more than 20% to 170.60 kroner by early afternoon trading.
The first European case was confirmed on May 7, 2022, in an individual who returned from a travel to Nigeria, where monkeypox is endemic. Subsequently, more than 20 cases have been confirmed across England, Portugal and Spain with additional suspected cases currently being investigated. Evidence points to that most of the infections have been acquired locally in these countries. In the US, a single case has been confirmed in a traveler from Canada, where no cases are yet confirmed, but several remain under investigation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze